Hidroxocobalamina Basi (Hydroxocobalamin Chloride)

Hidroxocobalamina Basi is a vitamin B12 product containing hydroxocobalamin chloride as the active ingredient. It is supplied in an injectable form for intramuscular administration and is marketed in the European Union. The preparation provides a source of vitamin B12 for patients with deficiency, supporting normal hematologic and neurologic function. It is intended for use under medical supervision and may be prescribed for individuals with documented cobalamin deficiency or related anemia.

Hidroxocobalamina Basi is used primarily to correct and prevent vitamin B12 deficiency and its clinical consequences.

- Treatment of cobalamin deficiency confirmed by laboratory testing. - Management of megaloblastic anemia caused by insufficient vitamin B12. - Support for patients with malabsorption syndromes such as pernicious anemia or gastrointestinal surgery. - Adjunct therapy in certain metabolic disorders requiring methylmalonyl‑CoA mutase activity. - Prevention of deficiency in individuals receiving long‑term nitrous oxide anesthesia or certain medications.

Adverse reactions to intramuscular hydroxocobalamin are generally uncommon but may occur.

Common: - Transient injection‑site pain or erythema. - Mild headache. - Nausea or mild gastrointestinal discomfort. - Flushing or a temporary reddish skin discoloration.

Serious: - Anaphylactic or severe hypersensitivity reactions. - Significant hypotension or cardiovascular collapse. - Acute hemolytic events in patients with rare enzyme deficiencies. - Severe skin reactions such as Stevens‑Johnson syndrome.

When prescribing Hidroxocobalamina Basi, clinicians should consider several precautionary measures to ensure safe use.

- Assess vitamin B12 status before initiating therapy to confirm deficiency. - Use caution in patients with known hypersensitivity to hydroxocobalamin or other cobalamin preparations. - Monitor for signs of allergic reaction during and after injection. - Evaluate renal or hepatic impairment, as altered metabolism may affect drug handling. - Avoid intramuscular injection into areas with poor circulation or infection. - Consider pregnancy and lactation status; data are limited, so use only if benefit outweighs potential risk. - Review concomitant use of medications that may mask B12 deficiency symptoms.

Hydroxocobalamin can interact with certain drugs, influencing absorption or clinical effect.

Avoid: - Intravenous nitrous oxide, which inactivates vitamin B12 and may exacerbate deficiency. - High doses of folic acid that can mask hematologic signs of B12 deficiency. - Certain antibiotics (e.g., chloramphenicol) that may impair cobalamin synthesis.

Use with caution: - Metformin, which may reduce vitamin B12 absorption over long‑term use. - Proton pump inhibitors or H2‑blockers that decrease gastric acidity and intrinsic factor activity. - Anticonvulsants such as phenytoin or carbamazepine, which may increase B12 requirements.